Publications by authors named "Simone A Brysland"
Article Synopsis
- Patients with Waldenström macroglobulinemia (WM) experience symptoms like cytopenias, fatigue, and bleeding, often exacerbated by therapeutics like Bruton's tyrosine kinase inhibitors (BTKis).
- A study analyzed hemostatic dysfunction in WM patients, comparing samples from untreated patients, those on BTKis, and healthy donors, using various blood tests to assess platelet function and clotting potential.
- Results showed that WM patients had decreased platelet reticulation, slower thrombin generation, and impaired hemostatic function due to high levels of IgM, indicating serious disturbances in blood coagulation despite receiving treatment.
Waldenström macroglobulinemia (WM) is a rare, incurable, low-grade, B cell lymphoma. Symptomatic disease commonly results from marrow or organ infiltration and hyperviscosity secondary to immunoglobulin M paraprotein, manifesting as anemia, bleeding and neurological symptoms among others. The causes of the bleeding phenotype in WM are complex and involve several intersecting mechanisms.
View Article and Find Full Text PDF